Aardvark Therapeutics Reports 2026 Annual Meeting Results

What Happened
Aardvark Therapeutics, Inc. (AARD) filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders held on August 14, 2026. Of 21,884,158 shares outstanding as of the June 18, 2026 record date, 11,992,479 shares (≈54.79%) were represented, establishing a quorum. Stockholders elected two Class I directors—Victor Tong, Jr. and Jeffrey Chi, Ph.D.—ratified BDO USA, P.C. as the company’s independent registered public accounting firm for 2026, and approved the repricing of certain outstanding stock options under the company’s equity plans.

Key Details

• Meeting date and quorum: Annual Meeting held Aug 14, 2026; record date Jun 18, 2026; 11,992,479 shares represented (~54.79% of 21,884,158 outstanding).
• Director elections (terms through 2029): Victor Tong, Jr. — 6,264,929 votes for, 1,898,132 withheld, 3,829,418 broker non-votes; Jeffrey Chi, Ph.D. — 6,426,038 for, 1,737,023 withheld, 3,829,418 broker non-votes.
• Auditor ratification: BDO USA, P.C. ratified as independent auditor for year ending Dec 31, 2026 — 11,877,567 for, 24,018 against, 90,894 abstentions.
• Option repricing approved: Repricing of certain outstanding stock options under the 2017 Plan, 2025 Plan and 2025 Inducement Plan passed — 4,649,269 for, 3,439,983 against, 73,809 abstentions, and 3,829,418 broker non-votes.

Why It Matters

• Board continuity: Election of the two Class I directors maintains the company’s board composition through the 2029 annual meeting, affecting governance and strategic oversight.
• Financial reporting continuity: Ratifying BDO as auditor confirms the firm that will audit 2026 financial statements, relevant to investor confidence and reporting processes.
• Capital structure and compensation impact: Approval to reprice eligible stock options can affect employee incentives, potential dilution, and future share‑based compensation expense; investors should monitor subsequent disclosures for the scope and accounting impact of repricings.